Tumor immunology--towards a paradigm of reciprocal research

Seminars in Cancer Biology
Charles G Drake, Drew M Pardoll

Abstract

Recent advances in the field of tumor immunology highlight the difficulties involved in generating and maintaining a tumor-specific immune response. The tendency of T cells to be tolerized in vivo, and the tendency of tumors to escape immune recognition represent significant barriers to successful immunotherapy. The results of early clinical trials illustrate these points and underscore the critical importance of an interactive dialog between laboratory and clinical research efforts.

Citations

Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Laura A VellaOlivera J Finn
Oct 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Nishant AgrawalBert Vogelstein
Oct 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger K StrairEdmund C Lattime
Sep 10, 2003·Hematology/oncology Clinics of North America·Keith L KnutsonMary L Disis
Jul 1, 2003·Expert Review of Neurotherapeutics·Keith L KnutsonMary L Disis
Jul 28, 2004·Stem Cells·Alessio Nencioni, Peter Brossart
Sep 16, 2008·Cancer Immunology, Immunotherapy : CII·Calin D DumitruGary W Gullikson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Seminars in Cancer Biology
Miguel-Angel PeralesAlan N Houghton
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Wendy J PickfordRobert N Barker
© 2022 Meta ULC. All rights reserved